Proteolytic Modifications of Lipoprotein(a): Potential Relevance to its Postulated Atherothrombogenic Role

Journal of Investigative Medicine

Volumn 46, Issue 8, 1998, Pages 359-363

  Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ANIMAL; ARTERIOSCLEROSIS; BLOOD; CHEMISTRY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PROTEIN PROCESSING; REVIEW; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; LIPOPROTEIN(A); PROTEIN PROCESSING, POST-TRANSLATIONAL; THROMBOSIS;

EID: 0032186119     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lawn RM, Scanu AM. Lipoprotein(a). In: Fuster V, Ross R, Topol EJ, eds. Coronary artery disease. Philadelphia: Lippincott-Raven Publishers, 1996:151-61.
2. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and molecular bases of inherited disease. 7th ed., vol. 2, New York: McGraw Hill, 1995:1887-912.
3. Jauhiainen M, Koskinen P, Ehnholm C, Frick, MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
4. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-99.
5. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
6. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992;360:670-2.
7. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, Young SG, Hammer RE, Sanan DA, Hobbs HH. Relative contributions of apolipoprotein(a) and apolipoprotein B to the development of fatty lesions in the proximal aorta of mice.
8. Hajjar HA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
9. Miles LA, Fless GM, Levine EG, Scanu AM, Plow EF. A potential role for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-3.
10. McCormick SPA, Linton MF, Hobbs HH, Taylor S, Curtiss LK, Young SG. Expression of human apolipoprotein B90 in transgenic mice. Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein(a). J Biol Chem 1994;269:24284-9.
11. Callow MJ, Rubin EM. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995;270:23914-7.
12. Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, Hammer RE. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem 1992;267:24369-74.
13. Edelstein C, Davidson NO, Scanu AM. Oleates stimulates the formation of triglyceride-rich particles containing apo B100-apo(a) in long-term primary cultures of human hepatoyctes. Chem Phys Lipids 1994;67/68:135-43.
14. Bonen D, Hausman A, Hadjiagapiou C, Skarosi S, Davidson N. Expression of a recombinant apolipoprotein(a) in HepG2 cells. J Biol Chem 1997;272:5659-67.
15. White A, Rainwater D, Lanford R. Intracellular maturation of apolipoprotein(a) and assembly of lipoprotein(a) in primary baboon hepatoyctes. J Lipid Res 1993;34:509-17.
16. Scanu AM, Miles L, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, Hoover-Plow JL, Brunck T, Plow EF. Rhesus monkey lipoprotein(a) binds to lysine sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). J Clin Invest 1993;91:283-91.
17. Edelstein CM, Mandala D, Pfaffinger D, Scanu AM. Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry 1995;34:16483-92.
18. Ernst A, Helmhold M, Brunner C, Pethoschramm A, Armstrong VW, Muller HJ. Identification of two functionally distinct lysine binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995;270:6227-34.
19. Klezovitch O, Edelstein C, Scanu AM. Evidence that the fibrinogen binding domain of apo(a) is outside the lysine binding site (LBS) of kringle IV-10. A study involving naturally-occurring lysine binding defective lipoprotein(a) phenotypes. J Clin Invest 1996;98:185-91.
20. Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 1989;8:4035-40.
21. Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res 1996;37:1786-801.
22. Klezovitch O, Edelstein C, Zhu L, Scanu AM. Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycandecorin. Implications for the retention of lipoprotein(a) in atherosclerotic lesions. J Biol Chem 1998;37:23856-65.
23. Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. J Biol Chem 1997;272:11079-87.
24. Edelstein C, Italia JA, Klezovitch ON, Scanu AM. Metalloproteinase-2 cleaves lipoprotein(a) and apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Circulation 1997;96(Suppl):1-111.
25. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996;98:2414-24.
26. Bader G, Edelstein C, Shamburek RD, Nishiwak M, Nazih H, Schwartz C, Scanu AM, Brewer HB. Lp(a): comparison of the in vivo metabolism of apo(a) and Lp(a) in man. Circulation 1996;94(Suppl):36.
27. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997;100:2170-81.
28. Pepin JM, O'Neil JA, Hoff NF. Quantification of apo(a) and apo B in human atherosclerotic lesions. J Lipid Res 1991;32:317-27.
29. Hoff HF, O'Neil J, Yashiro A. Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res 1993;34:789-98.
30. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989;9:593-603.
31. Scanu AM. Lipoprotein(a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med, 1988;112:1045-47.
32. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
33. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K Zhang JL, Rubin EM Lawn RM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997;100:558-64.
34. Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger D, Lawn RM, Rubin EM. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997;100:1493-500.
35. Karmansky I, Shnader H, Palant A, Gruener N. Lysine-binding species of lipoprotein(a) in coronary artery disease. Eur J Clin Invest 1994;24:360-6.
36. Scanu AM, Pfaffinger D, Lee JC, Hinman J. A single point mutation (Trp72-Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta, 1994;1227:41-5.
37. Scanu AM, Atzeni MM, Edelstein C, Tonolo G, Maioli M, Klezovitch O. Lipoprotein(a): identification of subjects with a superbinding capacity for fibrinogen. Clin Genet 1997;52:367-70.
38. Libby P, Egan D, Skarlatos S. Role of infectious agents in atherosclerosis and thrombosis. Circulation 1997;97:4095-101.